TY  - GEN
AU  - Pozzilli,Paolo
AU  - Norwood,Paul
AU  - Jódar,Esteban
AU  - Davies,Melanie J
AU  - Ivanyi,Tibor
AU  - Jiang,Honghua
AU  - Woodward,D Bradley
AU  - Milicevic,Zvonko
TI  - Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
SN  - 1463-1326
PY  - 2018///0502
KW  - Aged
KW  - Diabetes Mellitus, Type 2
KW  - blood
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Monitoring
KW  - Drug Resistance
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glucagon-Like Peptide-1 Receptor
KW  - antagonists & inhibitors
KW  - Glucagon-Like Peptides
KW  - administration & dosage
KW  - Glycated Hemoglobin
KW  - analysis
KW  - Humans
KW  - Hyperglycemia
KW  - prevention & control
KW  - Hypoglycemia
KW  - chemically induced
KW  - Hypoglycemic Agents
KW  - Immunoglobulin Fc Fragments
KW  - Incretins
KW  - Injections, Subcutaneous
KW  - Insulin Glargine
KW  - Intention to Treat Analysis
KW  - Male
KW  - Middle Aged
KW  - Patient Dropouts
KW  - Recombinant Fusion Proteins
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/dom.12937
ER  -